Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIB003 Single Ascending Dose Study
NCT03545438Phase 1Completed
- Sponsor
- LIB Therapeutics
- Start
- Oct 2017
- Primary completion
- May 2018
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lerodalcibep in hypercholesterolemia (9 cohorts), sponsored by LIB Therapeutics. Primary endpoint: Incidence and severity of treatment emergent adverse events at 43 days. Started Oct 2017; status: completed.
02
Drugs
lerodalcibep
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT03545438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03545438.